Navigation Links
Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,,AN2690; Findings Published in Science

- Journal Article Also Demonstrates the Promise of Anacor's Boron-Based Chemistry in Developing Antibiotics -

PALO ALTO, Calif., June 21, 2007 /PRNewswire/ -- Anacor Pharmaceuticals, a privately held pharmaceutical company, announced today that the journal Science will publish results of research that details how AN2690, the company's lead clinical candidate, kills fungal cells by interfering with synthesis of a specific protein required for fungal growth. This unique mechanism of action, made possible by the company's boron-based chemistry, may also prove useful in developing new classes of therapeutic agents such as antibiotics. The research results will be published in the June 22 issue of the journal.

"Understanding the way in which AN2690 stops fungal infections has given us a wealth of information about how to fashion antimicrobial drugs, including other anti-fungal compounds and systemic antibiotics," said Dickon Alley, Ph.D., head of discovery biology at Anacor and an author of the Science paper. "These findings validate our scientific strategy of focusing on the largely untapped potential of boron-containing drug candidates for unmet medical needs."

AN2690 is in Phase 2 clinical trials for the treatment of onychomycosis, a fungal infection of the nails and nailbeds that affects 7 to 14 percent of the U.S. population. Earlier this year, Anacor signed a partnership agreement with Schering-Plough Corporation to develop and commercialize AN2690. Under the terms of the agreement, Anacor received a $40 million upfront payment and a $10 million financing commitment from Schering-Plough. The company is eligible to receive payments potentially exceeding $575 million for development, regulatory and commercial milestones.

From a family of compounds known as benoxaborales, AN2690 demonstrated potent anti-fungal properties during preclinical testing. Anacor researchers and collaborators from th
'"/>




Page: 1 2 3

Related medicine technology :

1. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
2. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
3. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
4. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
5. NIDA Study Identifies Genes That Might Help Some People Abstain from Smoking
6. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
11. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
Post Your Comments:
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
(Date:7/9/2014)... Infectious Diseases (NIAID), part of the National Institutes ... of CRS3123, an investigational oral antibiotic intended to ... ) infection. CRS3123 (previously known as REP3123) is ... while sparing normal intestinal bacteria. , The Phase ... men and women ages 18 to 45 in ...
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts ... among adults with intellectual and developmental disabilities, the likelihood ... receiving dental care increased. The findings, published in the ... may help improve interventions designed to address the oral ... researchers reviewed the dental records of 107 patients at ...
(Date:7/9/2014)... older age with kidney and heart disease have raised ... older adults. However, in the first study to look ... of Medicine at the University of Pennsylvania report that ... life expectancy and cardiovascular health as very healthy older ... of the ever increasing organ transplant waitlists, the authors ...
(Date:7/9/2014)... published in the scientific journal Nature Neuroscience ... at Universit Laval, reveals that it is possible to ... rekindling pain so that it can subsequently be erased. ... chronic pain. , The researchers from the Faculty of ... mentale de Qubec (IUSMQ) were inspired by previous work ...
Breaking Medicine News(10 mins):Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:Discovery of a new means to erase pain 2
... 6 million international research consortium to strengthen knowledge of how ... most effectively rebuilt. The REBUILD programme, funded ... will focus on health financing, human resources and their interaction. ... aim to build knowledge about the implications for women, girls ...
... dialysis see their lives inevitably affected by the treatment. ... these kidney patients has improved very little, although it ... starting point, Dr Begoa Ruiz de Alegra studied the ... treatment and domiciliary peritoneal dialysis) in the Basque Country ...
... medicine is one of today,s most exciting scientific and ... ,firsts, new rulings by regulatory bodies or ethical controversies. ... the field, ethicists, legislators, the media and the public. ... than 9,000 of the world,s leading experts in reproductive ...
... People with immune-related disorders such as rheumatoid arthritis and lupus ... clots during hospital stays, a new study has found. ... analyzed 45 years, worth of medical records of patients who ... prior history of blood clots in a vein, also called ...
... research from UC Davis Cancer Center has found that whether ... where they live in addition to their race or ethnicity. ... lower colorectal screening rates than whites, presumably because of differences ... hasn,t been known, until now, is whether these differences also ...
... blood tests require shipping a vial of blood to a laboratory ... device invented by a team of engineers and students at the ... a portable device that provides results in less than 30 minutes. ... testing can be performed in a clinic, in a doctor,s office, ...
Cached Medicine News:Health News:LSTM leads new £6 million ($9.3 million) health systems knowledge consortium 2Health News:Ph.D. thesis shows why patients subjected to dialysis face their illness in different ways 2Health News:Ph.D. thesis shows why patients subjected to dialysis face their illness in different ways 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Immune Disorders May Raise Blood Clot Risk in Hospitalized Patients 2Health News:For non-whites, geography plays key role in colon cancer screening 2Health News:For non-whites, geography plays key role in colon cancer screening 3Health News:Engineering team invents lab-on-a-chip for fast, inexpensive blood tests 2
24-Well Slot Blot...
... Disposable, clear, APET plastic tray. Ideal for ... those trays used for multipurposes. Pour spouts ... A marker or label may be used ... trays on rockers or shakers for staining ...
... with vacuum stage, porous vacuum plate, reservoir seal ... The Model 785 vacuum blotter quickly and ... gel onto a nylon membrane. Because it generally ... acid samples can be separated on a gel, ...
... vacuum stage, porous vacuum plate, reservoir seal O-ring, ... The Model 785 vacuum blotter quickly and efficiently ... onto a nylon membrane. Because it generally requires ... samples can be separated on a gel, transferred ...
Medicine Products: